45,373 Shares in Merck & Co., Inc. $MRK Acquired by SG Trading Solutions LLC

SG Trading Solutions LLC purchased a new position in Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 45,373 shares of the company’s stock, valued at approximately $4,776,000. Merck & Co., Inc. makes up approximately 1.1% of SG Trading Solutions LLC’s portfolio, making the stock its 16th largest position.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. during the 4th quarter valued at $25,000. Prosperity Bancshares Inc bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $26,000. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. during the fourth quarter valued at about $26,000. IFC & Insurance Marketing Inc. acquired a new position in shares of Merck & Co., Inc. during the fourth quarter valued at about $31,000. Finally, High Note Wealth LLC increased its position in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The U.S. FDA approved an additional indication for CAPVAXIVE, Merck’s pneumococcal vaccine, expanding its use to children and adolescents ages 2 through 17 at increased risk for pneumococcal disease. The expanded label could support longer-term sales growth and reinforces Merck’s vaccine franchise. Article Title
• Neutral Sentiment: Merck also announced broader corporate activity around AI drug discovery with Protillion Biosciences and a global HPV awareness campaign, which may help pipeline development and brand visibility over time but are not immediate revenue drivers. Article Title
• Neutral Sentiment: A separate survey from Merck Animal Health highlighted unmet needs in treating canine allergic skin disease, suggesting future product opportunity, but it is a relatively small and less immediate catalyst for the stock. Article Title
• Negative Sentiment: Despite the FDA win, MRK has still been trading lower recently, reflecting broader weakness in the shares and suggesting investors may be waiting for more evidence that new and existing products can offset slower growth in other parts of the portfolio. Article Title

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on MRK shares. Royal Bank Of Canada restated an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a report on Monday, March 30th. Citigroup began coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target for the company. Barclays began coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective for the company. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Finally, JPMorgan Chase & Co. lifted their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research report on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $114.04 on Friday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The firm has a 50-day moving average of $116.12 and a 200-day moving average of $113.60. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $125.14. The company has a market cap of $281.65 billion, a P/E ratio of 32.12, a P/E/G ratio of 2.60 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same period in the previous year, the company earned $2.22 earnings per share. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.